Bio-Techne filed a supplemental disclosure regarding its proposed merger with Merck KGaA to address litigation alleging the Proxy Statement misrepresented or omitted material information. A shareholder lawsuit seeks to enjoin the special meeting scheduled for September 23, 2026. The filing updates financial data used by Goldman Sachs in its fairness opinion, citing approximately $421 million in LTM Adjusted EBITDA (Core) as of March 31, 2026, and total debt of approximately $200 million. Bio-Techne operates in the life sciences research tools industry.
